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Pediatric high-grade glioma (pHGG) and diffuse intrinsic
pontine glioma (DIPG) are invasive tumors with poor survival.
Oncolytic virotherapy, initially devised as a direct cytotoxic
treatment, is now also known to act via immune-mediated
mechanisms. Here we investigate a previously unreported
mechanism of action: the inhibition of migration and invasion
in pediatric brain tumors. We evaluated the effect of oncolytic
herpes simplex virus 1716 (HSV1716) on the migration and in-
vasion of pHGG and DIPG both in vitro using 2D (scratch
assay, live cell imaging) and 3D (spheroid invasion in collagen)
assays and in vivo using an orthotopic xenograft model of
DIPG invasion. HSV1716 inhibited migration and invasion
in pHGG and DIPG cell lines. pHGG cells demonstrated
reduced velocity and changedmorphology in the presence of vi-
rus. HSV1716 altered pHGG cytoskeletal dynamics by stabiliz-
ing microtubules, inhibiting glycogen synthase kinase-3, and
preventing localized clustering of adenomatous polyposis coli
(APC) to the leading edge of cells. HSV1716 treatment also
reduced tumor inﬁltration in a mouse orthotopic xenograft
DIPG model. Our results demonstrate that HSV1716 targets
the migration and invasion of pHGG and DIPG and indicates
the potential of an oncolytic virus (OV) to be used as a novel
anti-invasive treatment strategy for pediatric brain tumors.
INTRODUCTION
Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gli-
oma (DIPG) are invasive tumors associated with poor survival.1,2
Despite intensive treatment with surgery, radiotherapy, and chemo-
therapy, 5-year survival for pHGG remains low, at 15%–35%.1,3
DIPG is a major cause of neuro-oncology-related death in childhood,
with over 90% of children dying within 2 years of diagnosis.4–6 Stan-
dard treatment for DIPG includes 6 weeks of radiotherapy to stabilize
disease, prevent early progression, and improve neurological func-
tion; however, the effect on overall survival is minimal.4 There is
clearly a pressing clinical need to develop novel therapeutic strategies
to improve outcomes for these patients and one such avenue is to
target pHGG and DIPG migration and invasion,7 a well-known char-
acteristic of glioma cells.8,9
Oncolytic virotherapy offers a novel treatment approach for pHGG
and DIPG. Oncolytic viruses (OVs) are anti-cancer agents that are
capable of selectively infecting and lysing cancer cells, while leaving
normal tissue unharmed.10,11 Alongside their ability to kill infected
cancer cells, OVs can also generate an anti-cancer immune response,
by enhancing the immunogenicity of the tumor microenvironment
and activating innate and adaptive immune responses against in-
fected tumor cells.11 Thus, OVs have huge clinical potential for
poor prognosis tumors through their ability to act as selective cyto-
toxic and immunogenic agents.
However, very little is known about the effects of OVs on cancer cell
invasion and migration. Given that the cytoskeleton plays a critical
role in regulating the life cycle of infecting viruses,12–15 OVs may
be able to inﬂuence cancer cell migration through their interplay
with the host cancer cell cytoskeleton. If OVs have the potential to
inhibit cancer cell migration and invasion, this might contribute to
their therapeutic potential for poor prognosis invasive tumors such
as pHGG and DIPG.
In this study, we demonstrate that oncolytic herpes simplex virus
1716 (HSV1716) can speciﬁcally inhibit pHGG and DIPG migration
and invasion, highlighting a novel mechanism of action for an OV
against a principal hallmark of cancer. HSV1716 was evaluated in
this study, as it has previously been applied in early-phase trials for
high-grade gliomas.16–20 We also demonstrate that HSV1716 can
alter pHGG cytoskeletal dynamics, stabilizing microtubules and
altering molecular pathways critical for cell polarity, migration, and
movement. Finally, we show that infection of tumor cells with
HSV1716 reduced tumor inﬁltration in a mouse orthotopic xenograft
model of DIPG.
Received 16 April 2017; accepted 25 April 2017;
http://dx.doi.org/10.1016/j.omto.2017.04.002.
9These authors contributed equally to this work.
Correspondence: Julia V. Cockle, Leeds Institute of Cancer and Pathology, Uni-
versity of Leeds, Leeds LS9 7TF, UK.
E-mail: juliacockle@doctors.net.uk
Molecular Therapy: Oncolytics Vol. 5 June 2017 ª 2017 The Authors. 75
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
RESULTS
Oncolytic HSV1716 Can Inhibit Migration of pHGG Cell Lines in a
2D Scratch Assay
The ability of HSV1716 to block the migration of two pHGG cell
lines (SF188 and KNS42) was evaluated using a scratch assay
(Figure 1A).
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Figure 1. Oncolytic HSV1716 Can Inhibit Migration
of pHGG Cell Lines
Cell lines (SF188 and KNS42) were seeded into 24-well
plates at 1 ! 105 cells/well. After 24 hr, a scratch was
applied across themonolayer and wells were treated with
or without HSV1716 at 10 PFU/cell. (A) Plates were
imaged at !4 magnification in the IncuCyte ZOOM
incubator. Images shown are representative stills from
movies of SF188 and KNS42 created with IncuCyte
software at time 0 hr and 24 hr post-treatment. (B) Plates
were imaged at 0 hr and 24 hr using the EVOS cell im-
aging system at !4 magnification. Migration was quan-
tified from images using ImageJ software to determine
the percent change in the area of the scratch over 24 hr.
Graphs show means ± SEM from three individual ex-
periments (*p < 0.05 and ***p < 0.001 by one-way
ANOVA). (C) Cells (SF188, KNS42) were seeded at
1 ! 105 cells/well in a 12-well plate, left to adhere, and
then incubated with or without HSV1716 at 0.1, 1, 10, or
50 PFU/cell. At 24, 48, 72, or 96 hr, cells were harvested,
washed, and stained with LIVE/DEAD cell stain. The
percentage of dead cells was determined by FACS
analysis. Graphs show means ± SEM of three individual
experiments (*p < 0.05 and ***p < 0.001 by two-way
ANOVA).
HSV1716 at 1 or 10 plaque-forming units
(PFU)/cell signiﬁcantly reduced the migration
of SF188 cells, and HSV1716 at 10 PFU/cell
signiﬁcantly reduced migration of KNS42 cells
at 24 hr post-infection (Figure 1B).
To verify that the anti-migratory effect was not
a direct consequence of cytotoxicity, cell
viability was investigated using a LIVE/DEAD
assay (Figure 1C). At 24 hr (the time point for
analysis of the scratch assay), cell viability was
not signiﬁcantly affected by HSV1716, with
fewer than 6% dead cells being detected (Fig-
ure 1C). Additionally, pHGG cell proliferation,
as determined by the Ki67 intracellular ﬂuores-
cence-activated cell sorting (FACS) assay, was
not signiﬁcantly affected at 24 hr by HSV1716
treatment (data not shown).
Although signiﬁcant cytotoxic effects were
observed in SF188 cells at later time points
following treatment with HSV1716 (Fig-
ure 1C), the level was quite low, with less
than 40% cell death seen at 96 hr post-infection. KNS42 cells
were highly resistant to HSV1716-induced cytotoxicity, with very
low levels of cell death observed at 96 hr after infection. Nonethe-
less, this indicates a potential dual mechanism of action for
HSV1716 via inhibition of tumor cell migration and also via direct
cytotoxic effects.
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Oncolytic HSV1716 Can Inhibit Invasion of pHGG and DIPG Cell
Lines in 3D Spheroid Assays
A 3D tumor spheroid assay was used to investigate the effects of
oncolytic HSV1716 on pHGG and DIPG invasion. Tumor spheroids
of each cell line (SF188, KNS42) were encased in a collagen matrix
and then overlaid with HSV1716 at varying concentrations. Tumor
spheroid invasion was imaged over 72 hr using the EVOS cell imaging
system (Figure 2A). A migration index (MI) was calculated from the
images obtained and was used to evaluate the invasion front and
leading edge zone for each treatment. As previously described, these
zones are deﬁned as the area into which the bulk of migrating cells
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Figure 2. Oncolytic HSV1716 Can Inhibit Invasion of
pHGG and DIPG Tumor Spheroids
Tumor spheroids (SF188, KNS42, DIPG) were encased in
collagen and incubated with or without HSV1716 at
10 PFU/cell for 72 hr. (A) SF188 and KNS42 tumor
spheroid invasion was evaluated at 24, 48, and 72 hr
using the EVOS cell imaging system at!4 magnification.
The white scale bar represents 1,000 mm. Images shown
are representative of three individual experiments.
(B) SF188 tumor spheroids were encased in collagen and
incubated with or without HSV1716-GFP at 10 PFU/cell.
Plates were imaged at !4 magnification using the
IncuCyte ZOOM incubator over 70 hr. Images shown are
representative stills from movies created with IncuCyte
software, which were taken at around 0, 36, and 70 hr
post-treatment. The yellow scale bar represents 800 mm.
(C) Images generated from the EVOS cell imaging system
at 72 hr as described in (A) were analyzed using ImageJ
software by calculating the area of the invasion zone and
the leading edge zone. AMI for both the invasion zone and
the leading edge zone ((area of zone – area of core)O total
area) was calculated. Graphs show means ± SEM of
multiple repeats pooled from up to three individual exper-
iments (*p < 0.05, **p < 0.01, ***p < 0.001 by one-way
ANOVA). (D) Cells (SF188, KNS42, DIPG) at 1! 103 cells/
wellwere seeded inanultra-lowattachment round-bottom
96-well plate to formspheroid aggregates. Following72-hr
incubation, cells were incubated with or without HSV1716
at 0.1, 1, and 10 PFU/cell. Cell viability at 24, 48, 72, and
96 hr post-infection was determined by WST-1 assay and
is expressed as a percentage of controls. Graphs show
means ± SEM of three individual experiments for SF188
and KNS42 and two experiments for DIPG (*p < 0.05,
**p < 0.01, ***p < 0.001 by two-way ANOVA).
(75%) move and the area containing all the
migrating cells, respectively. To evaluate
whether HSV1716 could penetrate the collagen
matrix and infect cells, tumor spheroids were
encased in collagen and overlaid with medium
containing HSV1716-GFP at 10 PFU/cell.
GFP expression within SF188 spheroids was
detected within 36 hr (Figure 2B).
HSV1716 signiﬁcantly reduced invasion of
pHGG and DIPG tumor spheroids by 72 hr
(Figure 2C). A statistically signiﬁcant reduction in both the invasion
zone and leading edge zone at 72 hr was observed following treatment
with HSV at 10 PFU/cell for SF188 (means ± SEM are given unless
otherwise indicated; leading edge: control, 0.94 ± 0.004; and HSV at
10 PFU/cell, 0.63 ± 0.047; p < 0.001) and DIPG (leading edge: control,
0.75± 0.051; HSV at 10 PFU/cell, 0.52± 0.038; p = 0.0061; andHSV at
50 PFU/cell, 0.40 ± 0.041; p < 0.001). KNS42 spheroids appeared to be
more sensitive to HSV1716 and infection at 1 PFU/cell resulted in sig-
niﬁcant inhibition of migration (KNS42 leading edge: control, 0.42 ±
0.033; HSV at 1 PFU/cell, 0.23 ± 0.029; p = 0.0014; and HSV at
10 PFU/cell, 0.20 ± 0.05; p < 0.001). The observed effects were not
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due to the cytotoxic activity of the virus because the changes in migra-
tion were generally greater than the loss of viability (Figures 2C and
2D). For SF188 cells, there was an 8.13% or a 33.30% reduction in
the leading edge zone versus the control and a 10.13% or 41.30%
reduction in the invasion zone versus control, compared to 10.79%
or 15.36% loss of viability for 1 PFU/cell and 10 PFU/cell, respectively,
at 72 hr. For KNS42 cells, there was a 44.97% or 53.11% reduction in
the leading edge zone versus the control and a 48.50% or 53.30%
reduction in the invasion zone versus the control, compared to a
19.86% or 32.12% loss of viability for 1 PFU/cell and 10 PFU/cell,
A B
C
D E
Figure 3. Live Cell Imaging of pHGG Cell Lines
Reveals Differences in Cell Morphology and Velocity
Following Oncolytic HSV1716 Treatment
(A and B) Pediatric glioma cell lines SF188 (A) and KNS42
(B) were incubated with or without HSV1716 at 10 PFU/cell
in an Ibidi imaging dish. Live cell imaging was performed for
48 hr using the Nikon Biostation IM live cell imaging system.
Magnification !40. Stills were taken from time 0 hr at 2-hr
intervals from movies of SF188 (A) and starting at 12 hr
post-imaging start for KNS42 to allow for the reduced
motility of this cell line in comparison to SF188. (C) Tracking
analysis of the individual cell movements over 48 hr of
SF188 and KNS42 was performed from live cell imaging
movies using ImageJ with MTrack software following
treatment with or without HSV1716. (D and E) Quantification
analysis of velocity was obtained from live cell imaging using
ImageJ with MTrack software of both cell lines following
treatment with or without HSV1716. Graphs show the
means ± SEM obtained from five different fields of view
(***p < 0.001 by Student’s two-tailed t test).
respectively, at 72 hr. For DIPG cells, there were
19.68%, 30.43%, and 46.57% reductions in the
leading edge zone versus the control and
22.23%, 41.00%, and 56.35% reductions in the in-
vasion zone versus control compared to a 15.78%,
36.56%, and 46.87% loss of viability for 1, 10, and
50 PFU/cell, respectively, at 72 hr. Proliferation,
as determined by spheroid core size change over
time, did not increase signiﬁcantly following
HSV1716 treatment (data not shown).
Oncolytic HSV1716 Can Alter pHGG Cell
Morphology, Velocity, and Polarity
Given the data above showing that HSV1716
reduced the migration and invasion of glioma
cells, we hypothesized that we should see direct
changes in cell morphology, velocity, and polarity
following virus treatment.
To address this question, SF188 and KNS42 were
incubated with or without HSV1716 at 10 PFU/
cell and time-lapse imaging was performed over
48 hr (Movies S1, S2, S3, and S4). Virus treatment
markedly changed pHGG cell morphology (Figures 3A and 3B). Un-
treated SF188 cells were highly motile and polarized, with a distinct
front-rear axis deﬁning a leading protrusive front and a trailing
edge. The cell leading edge clearly protruded as ﬁlopodia and lamel-
lipodia and the trailing edge tail visibly retracted, progressing the cell
forward. After treatment, SF188 cells were notably less motile and
demonstrated a pronounced loss of polarity and a change in
morphology. SF188 HSV-treated cells became elongated with a loss
of their distinct leading and trailing edge and developed protrusive
tails that were unable to retract. Following HSV treatment, the
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SF188 cells appeared anchored to the surface and were unable to
generate the coordinated contractile forces required to propel the
cell forward. As previously documented, KNS42 cells were observed
to be overall much less motile than SF188. Untreated KNS42 cells ap-
peared to have diffuse, extended, and well-deﬁned lamellipodia,
which, unlike SF188, appeared to be orientated in opposite directions
with no clear front-rear deﬁnition. HSV1716 treatment of KNS42
cells resulted in cells rounding up with no discernable lamellipodia,
and the cells instead developed multiple thin-branching protrusions
(Figure 3B).
Tracking analysis conﬁrmed that pHGG cells treated with HSV1716
were much less motile than corresponding controls (Figure 3C). A
statistically signiﬁcant reduction in cell velocity was observed in
HSV1716-treated SF188 cells, although not in KNS42 cells (Figures
3D and 3E) (SF188 mean velocity: control, 0.33 ± 0.041 mm/min;
and HSV, 0.078 ± 0.007 mm/min; p < 0.001; KNS42 mean velocity:
control, 0.13 ± 0.014 mm/min; and HSV, 0.15 ± 0.022 mm/min;
p = 0.506).
Oncolytic HSV1716 Stabilizes pHGG Microtubules through
Accumulation of Post-translational Tubulin Modifications
Microtubules are polymers of a- and b-tubulin dimers that bind to
form stiff cylindrical hollow tubes that play a critical role in cell
migration.21 Microtubules are dynamic and can undergo polymeriza-
tion (growth) and depolymerization (shrinkage) during a process
known as dynamic instability, in order to search, explore, and interact
with cellular organelles and target sites.21–24While the majority of mi-
crotubules undergo dynamic instability with a relatively short half-
life, a subgroup of more “stable” microtubules demonstrate longer
half-lives. This increased microtubule stability is directly reﬂected
through the accumulation of post-translational tubulin modiﬁcations
including acetylation and detyrosination.21,24,25 These more stable
microtubules are more resistant to disassembly and can facilitate
directional trafﬁcking and preferential transportation of organelles,
vesicles, or proteins within the cell.21,24,26,27 However, accumulation
of such post-translational modiﬁcations has been shown to reduce
focal adhesion turnover and subsequent cell migration.28 It is postu-
lated that more “dynamic” microtubules are required for cell
migration.29–31 Therefore, the ability of HSV1716 to stabilize
pHGG microtubules through the accumulation of post-translational
tubulin modiﬁcations was evaluated by western blotting and immu-
noﬂuorescence (IF). The expression of acetylated tubulin from
pHGG cell lysates treated with HSV at 10 PFU/cell was evaluated
by western blot, which showed that virus treatment of SF188 and
KNS42 cells somewhat increased the levels of acetylated tubulin at
24 and 48 hr (Figure 4A).
Acetylated and detyrosinated tubulin levels from pHGG cells treated
with or without oncolytic HSV1716 at 10 PFU/cell were quantiﬁed by
IF after 24 and 48 hr. Taxol was used as an internal control, as it is a
known microtubule stabilizing agent.32 HSV1716 treatment of SF188
cells at 10 PFU/cell resulted in a statistically signiﬁcant increase in
both acetylated and detyrosinated tubulin levels at 24 and 48 hr
compared to controls (mean intensity normalized to control: acety-
lated tubulin at 24 hr: control, 1 ± 0.785; and HSV, 513 ± 135,
p = 0.00427; acetylated tubulin at 48 hr: control, 1 ± 0.523; and
HSV, 246 ± 60.8; p < 0.001; detyrosinated tubulin at 24 hr: control,
1 ± 0.983; and HSV, 62.4 ± 22.2; p = 0.0186; detyrosinated tubulin
at 48 hr: control, 1 ± 0.397; and HSV, 4.5 ± 0.594, p < 0.001) (Figures
4B–4E). The effects of HSV treatment on SF188 acetylated and
detyrosinated tubulin levels were more marked than the effects of
100 nM Taxol.
HSV1716 treatment of KNS42 cells signiﬁcantly increased acetylated
tubulin at 48 hr (mean intensity normalized to control for acetylated
tubulin at 24 hr: control, 1 ± 0.997; and HSV, 11.5 ± 5.02; p = 0.0672;
acetylated tubulin at 48 hr: control, 1 ± 0.804; and HSV, 6,038 ± 2,272;
p = 0.0289) (Figure 4D). KNS42 appeared to be more sensitive to the
effects of Taxol than SF188, with statistically signiﬁcant increases in
both acetylated and detyrosinated tubulin following 24 and 48 hr of
treatment (mean intensity normalized to control: acetylated tubulin
at 24 hr: control, 1 ± 0.997; and Taxol, 24.8 ± 5.8; p = 0.00258; acet-
ylated tubulin at 48 hr: control, 1 ± 0.804; and Taxol, 5,727 ± 709;
p = < 0.001; detyrosinated tubulin at 24 hr: control, 1 ± 0.099; and
Taxol, 1.35 ± 0.12; p = 0.04; detyrosinated tubulin at 48 hr: control,
1 ± 0.084; and Taxol, 1.81 ± 0.34; p = 0.0475) (Figures 4D and 4E).
HSV1716 did not signiﬁcantly increase KNS42 expression of detyro-
sinated tubulin (Figure 4E). This is also in keeping with a drug screen
published by canSAR (http://cansar.icr.ac.uk) that identiﬁes Taxol as
a potent inhibitor of KNS42.
Oncolytic HSV1716 Can Decrease pHGG Glycogen Synthase
Kinase-3b Activity and Prevent Adenomatous Polyposis Coli
Localization
Glycogen synthase kinase (GSK)-3 is a serine/threonine protein
kinase that plays a key role in orchestrating cell migration through
regulation of cell structure, motility, adhesion, and cytoskeleton dy-
namics.33–35 We previously demonstrated the importance of GSK-3
in pHGG cell migration and invasion.7 In a study designed to inves-
tigate the mechanism of wild-type HSV spread, HSV was shown to
induce the formation of stable microtubule subsets through inactiva-
tion of GSK-3b in normal human dermal ﬁbroblasts.14 Since the
effects of HSV1716 on GSK-3 expression in human tumor cells are
currently unknown, we examined them in our pHGG cell lines.
HSV1716 treatment of SF188 or KNS42 cells appeared to increase
levels of the inactivated form of GSK-3b (phosphorylated GSK-3b
Ser9) and this effect was more marked at 24 hr than at 48 hr (Fig-
ure 5A). By contrast, HSV1716 treatment resulted in a trend toward
decreased levels of the activated form of GSK-3ab (Tyr216/279 phos-
phorylated GSK-3ab) for both pHGG cell lines at 24 and 48 hr (Fig-
ure 5B). Overall, HSV1716 treatment resulted in a trend toward
decreased total GSK-3b levels over 48 hr for both pHGG cell lines
(Figure 5C). Although the majority of the results described above
did not reach statistical signiﬁcance, they do represent a consistent
trend that ﬁts with the biological hypothesis, and small differences
in kinase activity may have large biological consequences. In addition,
www.moleculartherapy.org
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the techniques employed here measure total levels of cellular GSK-3b
activity, whereas morphologically localized modulation of the activity
of this kinase was previously shown to be functionally signiﬁcant in
migrating cells;21,33 this phenomenon could well be happening in
the cells examined here. This is accumulating support that oncolytic
HSV can decrease GSK-3b activity in pHGG cells, increasing the
inactive GSK-3 isoform and reducing the activating tyrosine of
GSK-3ab.
GSK-3 plays an important role in regulating the polarity of migrating
cells.33,36 Polarity cues result in the localized inhibition of GSK-3,
which promotes adenomatous polyposis coli (APC) clustering at
microtubule plus ends at the leading edge of cells, controlling the di-
rection of movement.36 Given that HSV1716 appears to decrease
GSK-3b activity in pHGG cells, we hypothesized that HSV1716 treat-
ment of pHGG cells would alter APC intracellular distribution.
Untreated SF188 cells demonstrated a clear localization of APC to the
leading edge of cells (Figure 5D). This effect was not notable for
KNS42, possibly a reﬂection of the fact that this cell line was much
less motile than SF188 (Figure 5D). Following treatment with
HSV1716, SF188 cells demonstrated diffuse staining of APC
throughout the cytoplasm, with a clear loss of APC clustering to a
leading edge (Figure 5D). A similar diffuse distribution of APC was
seen in SF188 cells treated with the GSK-3 inhibitor 6-bromoindiru-
bin-oxime (BIO).
Oncolytic HSV1716 Treatment Reduced Tumor Infiltration and
Enhanced Therapy in a Mouse Orthotopic Xenograft Model
of DIPG
An orthotopic xenograft model of DIPG was established by injecting
HSJD-DIPG-007 cells into the fourth ventricle of non-obese diabetic
severe combined immunodeﬁciency (NOD SCID) mice, allowing
tumor cell growth and invasion into the brainstem. To evaluate the
effects of HSV1716 in this model, either HSJD-DIPG-007 cells pre-
mixed with PBS (control) or HSJD-DIPG-007 cells premixed with
HSV1716 at 10 PFU/cell were injected.
Analysis of mouse brain sections from the control group showed a
moderate increase in cellularity within the brainstem, adjacent cortex,
and cerebellum by diffusely inﬁltrating sheets of atypical glial cells
(Figures 6A and 6B). These cells had hyperchromatic and moderately
pleomorphic nuclei and ﬁne ﬁbrillary cytoplasm (Figure 6C). Mitotic
activity was high with no evidence of necrosis or vascular prolifera-
tion. These HSJD-DIPG-007 tumor cells did not form a solid mass
but appeared to migrate, invade, and inﬁltrate diffusely throughout
the midbrain, medulla, and cerebellum following their injection
into the brainstem (Figures 6A and 6B). Cell invasion reached the
subpial surface, where the cells then continued to spread horizontally
in clusters (Figure 6D).
Conversely, the brain sections obtained from mice that received an
intracranial injection of HSJD-DIPG-007 premixed with HSV1716
demonstrated well-contained collections of increased cellularity
within the brainstem, with very limited inﬁltration into the surround-
ing structures (Figure 6E). These well-contained collections consisted
of abnormal-looking cells with elongated nuclei and mixed with
apoptotic bodies, indicative of tumor cells (Figures 6F and 6G).
DISCUSSION
pHGG and DIPG are highly aggressive tumors associated with diffuse
inﬁltrative growth patterns.8,9 This invasive phenotype contributes
toward limited therapeutic response and, as such, there is a clear
need to develop new clinical therapies that effectively target tumor
migration and invasion. Oncolytic virotherapy for pHGG is under-re-
searched compared to adult brain tumors and there are currently no
published studies reporting the effects of OVs onDIPG. Furthermore,
there are no reported studies evaluating the effects of OVs on pHGG
or DIPG migration and invasion, making our study highly novel. We
have shown that the OV HSV1716 can inhibit the in vitro migration
and invasion of pHGG and DIPG cells. This is of high translational
relevance, as any residual cells resistant to the cytotoxic effects of
concomitant chemotherapy or OV would be unable to subsequently
inﬁltrate normal surrounding brain tissue, allowing for the possibility
of more targeted radiotherapy or second-look surgery, potentially
improving outcomes.
The possible mechanism by which HSV1716 may reduce pHGG
migration and invasion was also explored. HSV1716 altered pHGG
cytoskeletal dynamics, stabilizing microtubules through the accumu-
lation of post-translational tubulin modiﬁcations. Furthermore,
HSV1716 altered molecular pathways critical for cell polarity, migra-
tion, and movement. Virus treatment of pHGG cell lines resulted in a
tendency toward inhibited GSK-3b activity and prevented the local-
ized clustering of APC to the leading edge of the cell, a process depen-
dent on localized modulation of GSK-3b function.36
It is known that dynamic microtubules are required for cell migra-
tion.29–31 The accumulation of post-translational modiﬁcations
such as acetylated tubulin, which marks microtubules as stable,
have been shown to reduce focal adhesion turnover and subsequent
cell migration.28 Viruses have the ability to hijack components of
Figure 4. Oncolytic HSV1716 Stabilizes pHGG Microtubules through Accumulation of Post-Translational Tubulin Modifications
(A) pHGG cell lines SF188 and KNS42 were treated with or without HSV1716 at 10 PFU/cell. Following either 24- or 48-hr incubation, cell lysates were prepared and
expression of acetylated tubulin was determined by western blotting. (B and C) 2! 105 cells (SF188 and KNS42) were grown on sterile coverslips and treated with or without
HSV1716 at 10 PFU/cell or 100 nM Taxol for 24 or 48 hr. The effects of treatment at 24 and 48 hr on acetylated tubulin (B) and detyrosinated tubulin (C) expression were
evaluated by IF labeling, shown here for SF188. Red labeling, acetylated or detyrosinated tubulin; green labeling, tubulin; and blue labeling, DAPI staining. Magnification!63.
White scale bars represent 50 mm. (D and E) Between 40 and 80 cells from each treatment condition were evaluated to determine the intensity of acetylated (D) and de-
tyrosinated (E) tubulin labeling normalized to the control at 24 and 48 hr. Error bars show means ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001 by Student’s two-tailed t test).
www.moleculartherapy.org
Molecular Therapy: Oncolytics Vol. 5 June 2017 81
AB
C
D
(legend on next page)
Molecular Therapy: Oncolytics
82 Molecular Therapy: Oncolytics Vol. 5 June 2017
the cytoskeleton in order to facilitate their replication cycle and
spread, and this phenomenon has been reported for wild-type
HSV.14 Oncolytic HSV1716 also appears capable of stabilizing micro-
tubules, through accumulation of post-translational modiﬁcations
such as acetylated and detyrosinated tubulin in pHGG cells, and
this process may explain the reduction in pHGG motility, migration,
and invasion observed.
We previously showed that GSK-3b plays a key role in pHGG cell
migration and invasion.7 Our data suggest that HSV1716 may facili-
tate microtubule stabilization, and hence inhibit pHGG migration
and invasion, by increasing levels of the inactive form of GSK-3b.
These results are in keeping with the work of Naghavi et al.,14 who
showed that wild-type HSV-1 infection of primary human cell lines
can result in inactivation of GSK-3b by the action of the viral
serine/threonine kinase Us3, leading to the formation of stable micro-
tubules. Future work is required in order to further explore this mech-
anism using our virus in a pediatric brain tumor model. In addition,
we observed that the localized clustering of APC to the leading edge of
the cells was disrupted, a process that is dependent on functional
GSK-3b.36 The diffuse cellular APC localization may explain the
observed loss of cell polarity.
Finally, the ability of oncolytic HSV to inhibit glioma invasion was
explored in vivo. Mice receiving intracranial injection of DIPG cells
premixed with HSV1716 showed evidence of reduced tumor inﬁltra-
tion in an orthotopic xenograft model of DIPG compared to controls.
This work forms part of ongoing efforts to develop in vivo models of
Figure 5. Oncolytic HSV1716 Can Decrease pHGG GSK-3b Activity and Prevent APC Localization
pHGG cell lines SF188 and KNS42 were treated with or without HSV1716 at 10 PFU/cell. (A–C) Following either 24- or 48-hr incubation, cell lysates were prepared and
expression of phosphorylated GSK-3b Ser9 (inactivated form) (A), Tyr216/279 phosphorylated GSK3ab (active form) (B), and total GSK-3b (C) was determined by western
blotting. The b-actin control was included to evaluate protein loading and transfer. Intensity of each band was quantified and normalized to the b-actin control using ImageJ
software. Graphs show means ± SEM of three individual experiments (*p < 0.05 by Student’s two-tailed t test). (D) 2 ! 105 cells (SF188 or KNS42) were grown on sterile
coverslips and treated with or without oncolytic HSV at 10 PFU/cell or 5 mMBIO for 24 hr. The effects of treatment at 24 hr on APC localization (white arrows) were evaluated
by IF labeling. Red labeling, APC; green labeling, tubulin; and blue labeling, DAPI staining. Magnification ! 63. White scale bars represent 50 mm.
Figure 6. Oncolytic HSV1716 Reduced Tumor
Infiltration in a Mouse Orthotopic Xenograft Model
of DIPG
(A–G) 5 ! 105 disaggregated DIPG cells premixed with
PBS (A–D) or HSV1716 at 10 PFU/cell in PBS (E–G) were
stereotactically injected into the brains of 4- to 5-week-
old NOD SCID mice. Tumors were allowed to establish
and mice were euthanized when they showed signs of
disease (i.e., severe ataxia or > 15% weight loss). Brains
were harvested into 4% PFA, sliced into coronal sections,
embedded in paraffin, and sectioned to 4-mm thickness.
Tissue sections were stained with H&E. Images were
taken using the SPOT Insight camera and Leitz DMRB
microscope. Images from mouse brain obtained on day
62 post-surgery (A–D), day 123 post-surgery (E and F),
and day 78 post-surgery (G). (A) Brainstem section
at!2.5 magnification. (B) Section through the cerebellum
at !10 magnification. (C) Brainstem section of
pons at !20 magnification. (D) Section showing arach-
noid and pia at !20 magnification. Black arrows show
representative examples of diffusely infiltrating atypical
glial cells. (E) Cross-section of pons and cerebellum
at !2.5 magnification. Red arrow indicates a well-
contained section of abnormal-looking cells. (F) !40
magnification of the boxed area in (E). (G) Brainstem
section at !20 magnification. Black arrows show repre-
sentative examples of diffusely infiltrating atypical glial
cells. C, cerebellum; P, pons.
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glioma invasion in order to efﬁciently screen novel anti-invasive ther-
apies for pediatric brain tumors.
Oncolytic virotherapy offers a completely novel treatment approach
for poor prognosis children’s brain tumors. Although clinical experi-
ence for use in children with intracranial tumors is limited to a few
case reports,37 promising results have been demonstrated in adult
patients with high-grade glioma in terms of safety, tolerability, and
multiple dose delivery.16–20 Virus delivery across the blood-brain bar-
rier and to speciﬁc areas of the brain, including the brainstem in the
case of DIPG, must also be considered; however, novel techniques
such as positive pressure infusion using convection-enhanced deliv-
ery may be able to enhance viral distribution and target delivery.38
Additionally, for pHGG, intra-operative delivery of HSV1716 to the
residual macroscopic tumor or the tumor cavity would be a possibil-
ity, overcoming the need for virus to cross the blood-brain barrier.
We show here, for the ﬁrst time to our knowledge, that HSV1716 may
also have a role as an anti-invasive therapeutic. As such, oncolytic
HSV may have the potential to reduce tumor migration and inﬁltra-
tion from post-operative residual cancer cells. This additional mech-
anism of action against a principle hallmark of cancer further
highlights the huge clinical potential for such oncolytic virotherapy.
Furthermore, this anti-invasive mechanism of action could be valu-
able in the treatment of highly invasive tumors such as DIPG, which
are not amenable to surgical options.
Our data therefore support the case for the development of the clinical
application of oncolytic virotherapy for pHGG and DIPG and high-
light the therapeutic potential of an OV not only as a cytotoxic and
immunogenic treatment but also as an anti-invasive strategy.
MATERIALS AND METHODS
Cell Lines
Cell lines used in this study were the pediatric glioma cell lines SF188
and KNS42 (a kind gift from Prof. Chris Jones, Institute of Cancer
Research) and the patient autopsy-derived DIPG cell line HSJD-
DIPG-007 (a kind gift from Dr. Angel M. Carcaboso) hereafter
referred to as DIPG. Cell line identity (SF188 and KNS42) was veriﬁed
by serial tandem-repeat proﬁling (in-house testing at the Cancer
Research UK Leeds Centre genomics facilities). SF188, KNS42, and
DIPG cell lines were cultured as previously described.7 All cell lines
were tested and shown to be free of mycoplasma contamination.
Virus
Oncolytic HSV1716 (which carries the ICP34.5 deletion of a
neurovirulence gene to enhance safety) at a stock concentration of
1 ! 109 PFU/mL was obtained from Virttu Biologics and stored
at "80#C in PBS. A GFP-expressing HSV1716 (HSV1716-GFP) was
also obtained from Virttu Biologics at the same stock concentration.
Scratch Migration Assay
Cells were seeded at 1 ! 105 cells/well into 24-well plates (Corning)
such that after 24 hr of growth, they reached 80%–90% conﬂuence
as a monolayer. After 24-hr incubation at 37#C, a line was drawn
on the underside of each well across the center with a ﬁne
marker. A scratch was applied across the center of the monolayer,
perpendicular to the marker line. After detached cells were removed,
culture medium with or without HSV1716 at 50, 10, 1, 0.1, and
0.01 PFU/cell was added. Migration of cells across the scratch was
determined by imaging at 0 hr and 24 hr with the EVOS cell imaging
system (Thermo Fisher Scientiﬁc) at !4 magniﬁcation. Migration
was quantiﬁed using ImageJ software (https://imagej.nih.gov/ij;
NIH) to determine the percent change in the area of the scratch
from time zero to 24 hr.
Spheroid Invasion Assay
Spheroids were generated as previously described.7 Spheroids
embedded in collagen were incubated in 100 mL cell culture medium
with or without HSV1716 at 8 ! 102, 8 ! 103, 8 ! 104, or
4 ! 105 PFU/well, which approximates to a nominal 0.1, 1, 10, or
50 PFU/cell. Spheroid expansion and invasion into the collagen
matrix was imaged and analyzed as previously described7 and the
MI for 3D migration was determined. Two zones of migration were
deﬁned: the invasion zone, representing the area outside the spheroid
core into which approximately 75% of migrating cells invaded; and
the leading edge zone, representing the total area containing migrated
cells. The MI was calculated as ((area of zone " area of spheroid
core)O total area).
Live Cell Imaging of Adherent Cells
10 mL cells in 500 mL culture medium was placed in two of four quad-
rants of an Ibidi imaging dish (Nikon) and allowed to adhere for 2 hr
at 37#C. Equal volumes of medium were replaced in one quadrant
with HSV1716 at an approximation of 10 PFU/cell. The Ibidi dish
was then cultured in the incubation/imaging chamber of the Nikon
Biostation IM live cell imaging system. Cells were imaged for 48 hr
at 3-min intervals at 37#C with 5% CO2 in air. Cell tracking and anal-
ysis was carried out according to Cockle et al.7 For tracking, the nu-
cleus of each cell was identiﬁed and tracked over the 48-hr period at
150-min intervals using ImageJ with MTrack software (Biomedical
Imaging Group Rotterdam).
Live Cell Imaging of Spheroids
HSV1716 infection of spheroids was assessed by GFP expression
within spheroids infected with HSV1716-GFP. Collagen was overlaid
with cell culture medium with or without 8 ! 104 PFU/well of
HSV1716-GFP. Spheroids were imaged in the IncuCyte ZOOM incu-
bator (Essen BioScience) at 37#C with 5% CO2 in air using the !4
microscope objective, with images taken hourly for 70 hr. IncuCyte
software (Essen BioScience) was used to create movies and visualize
GFP expression.
WST-1 Assay
1 ! 103 cells/well in culture medium were seeded in an ultra-low
attachment round-bottom 96-well plate to form spheroid aggregates.
Following 72-hr incubation at 37#C, cells were treated with an equal
volume of culture medium with or without 8! 102, 8! 103, 8! 104,
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or 4 ! 105 PFU/well of HSV1716. At 24-hr intervals for up to 96 hr,
10 mL water soluble tetrazolium-1 (WST-1) (Roche) was added per
well and, after 4 hr, absorbance at 450 nm was detected using the
colorimetric microplate reader. Spheroid imaging and analysis was
according to Cockle et al.7
LIVE/DEAD Assay
Cells were seeded into 12-well plates (Corning) at 1! 105 cells/well in
2mL culturemedium and left to adhere for aminimumof 4 hr at 37#C.
Culture medium with or without HSV1716 at 50, 10, 1, 0.1, and
0.01 PFU/cell was then added to each well. Cells were harvested,
washed in PBS, and stainedwith LIVE/DEAD red ﬁxable stain accord-
ing to the manufacturer’s instructions (Thermo Fisher Scientiﬁc).
Cells were washed, ﬁxed in 1% paraformaldehyde (PFA) (Sigma-Al-
drich), and stored at 4#C until acquisition on the Attune ﬂow cytom-
eter (Thermo Fisher Scientiﬁc). Analysis was carried out using Attune
Flow Cytometric software (version 2.1; Thermo Fisher Scientiﬁc).
Immunofluorescence
To investigate the effects of HSV1716 on tubulin acetylation and
detyrosination, cells were treated with or without either HSV1716
at 10 PFU/cell or 100 nMTaxol (Selleckchem) for 24 to 48 hr. To eval-
uate the cellular location of APC, cells were grown under the same
conditions and treated with or without either HSV at 10 PFU/cell
or 5 mM BIO for 24 hr (Calbiochem).
Antibodies for IF studies were rat anti-tubulin fed following treatment
with (1:500; Serotec), mouse anti-acetylated tubulin (1:500; Sigma-Al-
drich), rabbit anti-detyrosinated a-tubulin (1:200; Abcam), rabbit
polyclonal M-APC (1:2,000; a kind gift from Prof. Inke Näthke),
and secondary antibodies at 1:500 (Alexa Fluor-conjugated reagents;
Molecular Probes). Nuclear staining was performed with DAPI
(Molecular Probes) at the recommended working concentrations.
For IF studies of acetylated and detyrosinated tubulin, the ﬂuores-
cence intensity of each image was calculated in ImageJ software using
a standard threshold across all images. The ﬂuorescence intensity was
then divided by the number of cells in each image to calculate the in-
tensity of acetylated or detyrosinated tubulin per cell.
Western Blotting
Cells were treated with or without HSV1716 at 10 PFU/cell and har-
vested at 24 or 48 hr, and cell lysates were obtained using RIPA buffer
containing 25 mL/mL protease inhibitor (Sigma-Aldrich). Proteins
(20–40 mg loaded per lane) were separated by SDS-PAGE and
transferred to nitrocellulose. Antibodies used were mouse anti-acety-
lated tubulin (1:5,000 dilution; Sigma-Aldrich), rabbit anti-b-actin
(1:2,000 dilution; Abcam), rabbit anti-GSK-3b (1:1,000 dilution;
Cell Signaling Technology), rabbit anti-phospho GSK-3b (Ser 9)
(1:100 dilution; Cell Signaling Technology), rabbit anti-GSK3
(f+b) (phospho Y216+Y279; 1:1,000 dilution; Abcam), and second-
ary horseradish peroxidase (HRP)-conjugated antibodies per the
manufacturer’s instructions (Dako and Thermo Fisher Scientiﬁc).
Proteins were detected by the addition of SuperSignal West Pico
Chemiluminescent substrate (Thermo Fisher Scientiﬁc) and were
visualized using the ChemiDoc MP imaging system (Bio-Rad) and
Image Lab (Bio-Rad) software. Protein band intensity was analyzed
using ImageJ software. The intensity of each band was normalized
to the corresponding b-actin control.
In Vivo Experiments
In vivo experiments were conducted at the Mayo Clinic Department
of Immunology and ethics approval was granted by the Mayo Foun-
dation Institutional Animal Care and Use Committee. NOD SCID
mice aged 4–5 weeks were purchased from The Jackson Laboratory.
DIPG neurospheres were disaggregated with TrypLE express stable
trypsin replacement enzyme without phenol red (Thermo Fisher
Scientiﬁc), counted the evening before surgery, and left in culture
overnight. Cells were collected immediately prior to surgery and re-
suspended in either 2 mL PBS (control) or 2 mL PBS containing
HSV1716 at 10 PFU/cell. To establish intracranial tumors, 5 ! 105
disaggregated HSJD-DIPG-007 cells (pre-treated with PBS or HSV)
were stereotactically injected into the brains of two groups of 4- to
5-week-old NOD SCID mice (The Jackson Laboratory) (n = 6 per
group). The injection location was "1X, "0.8Y, 5Z from the
bregma.39 Use of these coordinates targets the fourth ventricle but
allows the cells to still grow and invade into the brainstem and cere-
bellum. Tumors were allowed to establish and mice were euthanized
when they showed clinical signs of disease (i.e., severe ataxia or > 15%
weight loss). After mice were euthanized, their brains were immedi-
ately harvested into 4% PFA.
Analysis of Brain Tissue
Brains were transferred from 4% PFA to 70% ethanol and then sliced
into coronal sections. Brains were embedded in parafﬁn, followed by
sectioning to 4-mm thickness using a manual rotary microtome
(Leica) and mounted on glass slides. Tissue sections were stained
with H&E. Slides were analyzed with the help of a consultant neuro-
pathologist (Dr. Azam Ismail, Department of Histopathology,
St. James’s University Hospital), to identify the presence of brain tu-
mors and the invasion and migration of tumor cells into the sur-
rounding normal brain. Images were taken using the SPOT Insight
cameraand SPOT software (both from SPOT Imaging, Diagnostic
Instruments) with the Leitz DMRB (Leica) microscope at !5, !10,
or !20 magniﬁcation.
Statistical Analysis
Statistical analysis was carried out using Graph Pad Prism 6 software
(GraphPad Software). Statistical signiﬁcance betweenmultiple groups
was determined by ANOVA. Statistical signiﬁcance between two
groups was determined by the Student’s two-tailed t test. p values <
0.05 were considered statistically signiﬁcant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four movies and can be found
with this article online at http://dx.doi.org/10.1016/j.omto.2017.
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